Transcenta
Edit

Transcenta

http://www.transcenta.com/
Last activity: 09.04.2024
Categories: CenterDevelopmentExchangeFacilityInformationManufacturingMedtechProductResearch
Transcenta is a clinical stage biopharmaceutical company that fully integrates antibody-based biotherapeutics discovery, research, development and manufacturing. On September 29, 2021, Transcenta was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 06628. Transcenta has established global footprint, with Headquarters and Discovery, Clinical and Translational Research Center in Suzhou, Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Beijing, Shanghai and Guangzhou in China and in Princeton, US, and External Partnering Center in Boston and Los Angeles, US. Transcenta is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. For more information, please visit www.transcenta.com.
Website visits
12.1K /mo.
Mentions
60
Location: United States, Massachusetts, Boston
Employees: 201-500
Total raised: $105M
Founded date: 2019
LinkedIn
Email

Investors 1

DateNameWebsite
17.07.2021ARCH Ventu...archventur...

Funding Rounds 1

DateSeriesAmountInvestors
23.12.2020-$105M-

Mentions in press and media 60

DateTitleDescriptionSource
09.04.2024Transcenta Announces Collaboration with Agilent to Develop a...PRINCETON, N.J. and SUZHOU, China, April 9, 2024 /PRNewswire/ -- Transcenta Holding Limited ("T...en.prnasia...
13.12.2023Transcenta Announces the Publication of Preclinical Results ...PRINCETON, N.J. and SUZHOU, China, Dec. 13, 2023 /PRNewswire/ -- Transcenta Holding Limited ("T...en.prnasia...
23.10.2023Transcenta Unveils Updated Efficacy Data from Osemitamab (TS...Latest data reveals a 55% confirmed response rate, median duration of response (DoR) and median prog...en.prnasia...
04.10.2023FDA Grants Transcenta Clearance to Proceed with Global Phase...Osemitamab (TST001) on Track to Become a Global Therapy that Elevates the Current Standard of Care f...en.prnasia...
16.08.2023Transcenta to Present Three Study Results at ESMO 2023SUZHOU, China, Aug. 16, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HK...en.prnasia...
31.07.2023Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Bloso...SUZHOU, China, July 31, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HK...en.prnasia...
07.07.2023Transcenta Received Approvals from China CDE and South Korea...SUZHOU, China, July 7, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKE...en.prnasia...
30.06.2023Transcenta Presented PFS Data by CLDN18.2 Expression Level f...64 patients with CLDN18.2 positive G/GEJ cancer were enrolled in TranStar102 (TST001-1002). CLDN18.2...en.prnasia...
06.06.2023Transcenta Presents Updated Data of Osemitamab (TST001) in C...SUZHOU, China, June 6, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKE...en.prnasia...
02.06.2023Transcenta Holding Limited (6628.HK) to Hold 2023 ASCO Busin...SUZHOU, China, June 2, 2023 /PRNewswire/ -- The management team of Transcenta Holding Limited (06628...en.prnasia...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In